Arcus Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-353.0M | $-283.0M | $-307.0M | $-267.0M | $53.0M | $-123.0M | $-84.7M | $-49.6M |
| Depreciation & Amortization | $10.0M | $10.0M | $8.0M | $6.0M | $4.0M | $3.0M | $3.6M | $3.7M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $60.0M | $76.0M | $73.0M | $65.0M | $55.0M | $22.0M | $9.0M | $3.9M |
| Net Cash from Operating Activities | $-482.0M | $-170.0M | $-306.0M | $438.0M | $-256.0M | $111.0M | $-73.5M | $-43.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $2.0M | $6.0M | $24.0M | $6.0M | $26.0M | $3.0M | $1.9M | $3.7M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $66.0M | $-84.0M | $194.0M | $-413.0M | $-4.0M | $-434.0M | $59.2M | $-113.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | $94.0K | $0 |
| Net Cash from Financing Activities | $488.0M | $277.0M | $33.0M | $33.0M | $237.0M | $439.0M | $1.1M | $129.1M |
| Net Change in Cash | $72.0M | $23.0M | $-79.0M | $58.0M | $-23.0M | $116.0M | $-13.1M | $-27.4M |
| Free Cash Flow | $-484.0M | $-176.0M | $-330.0M | $432.0M | $-282.0M | $108.0M | $-75.4M | $-46.7M |